Gemfibrozil

How to order Gemfibrozil

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Gemfibrozil on Prescriptsy

Gemfibrozil is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Gemfibrozil is a prescription-only medicine belonging to the fibrate class of lipid-regulating drugs.

It is used to lower high triglyceride levels in the blood and to treat mixed dyslipidaemia, a condition in which both triglycerides and cholesterol levels are abnormal.

Gemfibrozil is available as 300 mg capsules and 600 mg tablets and is taken by mouth, usually twice daily before meals.

It acts by activating a receptor in the liver called PPAR-alpha, which increases the breakdown of triglyceride-rich lipoproteins and boosts levels of protective HDL cholesterol.

This page provides a comprehensive clinical overview of gemfibrozil, including how it works, who should take it, dosing guidance, potential side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about gemfibrozil

• Gemfibrozil is a prescription-only medicine (POM) that requires regular blood test monitoring.
• Do not take gemfibrozil with simvastatin. Combining gemfibrozil with any statin significantly increases the risk of serious muscle damage.
• Report unexplained muscle pain, tenderness, or weakness to your GP immediately.
• Tell your prescriber about all other medicines you are taking, including over-the-counter products and herbal remedies.
• Gemfibrozil should not be used during pregnancy or breastfeeding.

Understanding hypertriglyceridaemia and dyslipidaemia

Triglycerides are a type of fat (lipid) found in the blood. They are the main form in which the body stores energy from dietary fat and carbohydrates.

While triglycerides are essential for normal metabolism, persistently elevated levels increase the risk of cardiovascular disease (heart attack and stroke) and, at very high levels, acute pancreatitis (a potentially life-threatening inflammation of the pancreas).

In the UK, dyslipidaemia is extremely common. The Health Survey for England has consistently shown that a substantial proportion of adults have lipid levels above recommended targets.

While much of cardiovascular risk reduction focuses on lowering LDL cholesterol (usually with statins), managing elevated triglycerides is also important, particularly in patients with very high levels (above 10 mmol/L, which carries a risk of acute pancreatitis) or in patients with metabolic syndrome, type 2 diabetes, or residual cardiovascular risk despite statin therapy.

Common causes of elevated triglycerides include obesity, excess alcohol consumption, poorly controlled type 2 diabetes, hypothyroidism, chronic kidney disease, certain medications (including corticosteroids, oestrogen therapy, and some antipsychotics), and genetic conditions such as familial hypertriglyceridaemia.

Identifying and addressing secondary causes is an essential first step before starting pharmacological treatment.

How gemfibrozil works: mechanism of action

Gemfibrozil is a fibric acid derivative that acts primarily through activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor expressed predominantly in the liver, kidney, heart, and skeletal muscle.

When PPAR-alpha is activated, it increases the transcription of genes involved in fatty acid beta-oxidation (the process by which the liver breaks down fatty acids for energy), upregulates lipoprotein lipase (the enzyme that removes triglycerides from circulating lipoproteins), and reduces hepatic production and secretion of VLDL, the main triglyceride-carrying lipoprotein.

The net result is a substantial reduction in circulating triglyceride levels, typically by 30 to 50%.

Gemfibrozil also increases HDL cholesterol by 10 to 20% through increased synthesis of apolipoproteins A-I and A-II, the major protein components of HDL.

The effect on LDL cholesterol is variable: in patients with predominantly raised triglycerides, LDL may actually increase as triglyceride levels fall (because VLDL remnants are more efficiently converted to LDL).

In patients with mixed dyslipidaemia, a modest reduction in LDL may be seen.

Gemfibrozil also has effects beyond lipid lowering that may contribute to cardiovascular protection.

It has anti-inflammatory properties, reduces plasma fibrinogen levels (a clotting factor associated with cardiovascular risk), and improves insulin sensitivity.

However, the clinical significance of these pleiotropic effects is less well established than the lipid-modifying actions.

Clinical evidence and UK prescribing guidance

The landmark Helsinki Heart Study (1987) demonstrated that gemfibrozil reduced the incidence of coronary heart disease events by 34% in men with primary dyslipidaemia, primarily through triglyceride reduction and HDL elevation.

The VA-HIT (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial) showed that gemfibrozil reduced cardiovascular events by 22% in men with established coronary heart disease, low HDL cholesterol, and relatively normal LDL cholesterol, demonstrating benefit in a population where statin therapy alone may not have addressed the underlying lipid abnormality.

NICE guideline CG181 on cardiovascular disease risk assessment and lipid modification recommends that statins are the first-line pharmacological treatment for cardiovascular risk reduction.

Fibrates are not routinely recommended as add-on therapy to statins for cardiovascular risk reduction in the general population.

However, gemfibrozil and other fibrates retain an important role in specific clinical scenarios: treatment of severe hypertriglyceridaemia (above 10 mmol/L) to prevent pancreatitis, management of familial hypertriglyceridaemia, and treatment of dyslipidaemia in patients who cannot tolerate statins.

The BNF lists gemfibrozil alongside fenofibrate and bezafibrate as fibrate options.

It specifically warns about the increased risk of rhabdomyolysis when gemfibrozil is combined with statins and notes that fenofibrate is the preferred fibrate if combination with a statin is necessary.

Gemfibrozil compared with other fibrates

Three fibrates are available in the UK: gemfibrozil, fenofibrate, and bezafibrate. All share the same basic mechanism (PPAR-alpha activation) but differ in important ways.

Fenofibrate is the most commonly prescribed fibrate in current UK practice, largely because it can be more safely combined with statins.

Gemfibrozil inhibits the glucuronidation and hepatic uptake of statins (particularly via OATP1B1), significantly increasing statin plasma levels and the risk of myopathy.

Fenofibrate does not share this pharmacokinetic interaction and has a substantially lower risk of muscle toxicity when used alongside a statin.

Gemfibrozil has the strongest evidence base for cardiovascular event reduction among the fibrates, thanks to the Helsinki Heart Study and VA-HIT trial.

Fenofibrate has been studied in the FIELD and ACCORD-Lipid trials, with more modest and less consistent cardiovascular benefits.

However, in modern practice, where most patients at cardiovascular risk are already taking a statin, the inability to safely combine gemfibrozil with statins limits its clinical utility.

Bezafibrate is a non-selective PPAR agonist (activating alpha, gamma, and delta receptors) and is sometimes used in patients with insulin resistance and metabolic syndrome.

It may have a more favourable effect on glycaemic control than gemfibrozil or fenofibrate.

Your prescriber will choose the most appropriate fibrate based on your lipid profile, other medications, and clinical circumstances.

Dosage and administration

The recommended dose of gemfibrozil is 600 mg twice daily, taken 30 minutes before the morning and evening meals.

Alternatively, 1,200 mg may be given as a single dose before the evening meal, although twice-daily dosing may be more effective for triglyceride lowering.

The maximum daily dose is 1,200 mg.

Gemfibrozil should always be taken in conjunction with continued dietary and lifestyle modifications.

These include reducing intake of refined carbohydrates and sugars, limiting alcohol consumption, maintaining a healthy weight, and increasing physical activity.

Addressing secondary causes of hypertriglyceridaemia (poorly controlled diabetes, hypothyroidism, excess alcohol) is essential.

Regular monitoring is required. Lipid profiles should be checked at baseline, 3 months, and then at least annually. Liver function tests should be monitored at similar intervals.

If there is no adequate lipid response after 3 months at full dose, gemfibrozil should be reviewed and potentially discontinued.

Side effects of gemfibrozil

Common side effects

Gastrointestinal symptoms are the most frequent, including indigestion, abdominal pain, nausea, diarrhoea, and flatulence. These are usually mild and may be minimised by taking gemfibrozil with food. They tend to improve over the first few weeks of treatment.

Serious side effects

Myopathy and rhabdomyolysis are the most serious potential adverse effects. Symptoms include unexplained muscle pain, tenderness, weakness, and dark brown urine.

The risk is highest when gemfibrozil is combined with a statin. Stop taking gemfibrozil and seek immediate medical attention if you develop these symptoms.

Hepatotoxicity (liver damage) with raised liver enzymes has been reported; regular liver function monitoring is recommended. Gemfibrozil increases the cholesterol content of bile and may promote gallstone formation.

When to seek medical help

Contact your GP or call NHS 111 if you experience persistent abdominal pain (particularly in the upper right abdomen, which may indicate gallstones), unexplained muscle symptoms, or yellowing of the skin or eyes.

Call 999 if you develop severe muscle pain with dark urine, signs of a severe allergic reaction (facial swelling, breathing difficulty), or chest pain.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Gemfibrozil must not be combined with simvastatin. Combination with other statins is generally avoided. The interaction with repaglinide is also contraindicated due to risk of severe hypoglycaemia.

Gemfibrozil potentiates warfarin; INR monitoring is essential if these drugs are used together.

Gemfibrozil is contraindicated in severe hepatic impairment, severe renal impairment, pre-existing gallbladder disease, and pregnancy or breastfeeding.

Patients should have lipid profiles, liver function tests, and full blood count monitored regularly. Creatine kinase should be checked if muscle symptoms develop. Treatment should be discontinued if there is no adequate lipid response after 3 months at full dose.

How to get gemfibrozil in the UK

Gemfibrozil is a prescription-only medicine available on the NHS. Your GP or a lipid specialist can prescribe it after assessing your cardiovascular risk factors and lipid profile.

Before prescribing, your doctor will ensure that dietary and lifestyle measures have been tried and that any secondary causes of hypertriglyceridaemia have been addressed.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also prescribe gemfibrozil following an appropriate clinical consultation.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Lifestyle measures for managing high triglycerides

Pharmacological treatment with gemfibrozil should always be accompanied by lifestyle modification. Reducing intake of refined carbohydrates, sugars, and saturated fats can substantially lower triglycerides.

Limiting alcohol is particularly important, as alcohol is a major driver of hypertriglyceridaemia. Weight loss of even 5 to 10% of body weight can significantly improve triglyceride levels.

Regular aerobic exercise (at least 150 minutes per week of moderate intensity) lowers triglycerides and raises HDL cholesterol independently of weight loss.

Optimising glycaemic control in patients with type 2 diabetes and treating hypothyroidism if present are essential steps that may reduce the need for fibrate therapy.

Sources

• Gemfibrozil 600 mg Tablets, Summary of Product Characteristics (EMC)
• Gemfibrozil, British National Formulary (BNF)
• NICE CG181: Cardiovascular disease: risk assessment and reduction
• High cholesterol, NHS
• MHRA Yellow Card Scheme